» Articles » PMID: 692379

Inhibition of Prolactin Release by Serotonin Antagonists in Hyperprolactinemic Subjects

Overview
Journal Metabolism
Specialty Endocrinology
Date 1978 Oct 1
PMID 692379
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Metergoline (4 mg) and methysergide (3 mg), two serotonin antagonists known to inhibit prolactin secretion in normal subjects, and the dopaminergic agonist, bromocriptine (2.5 mg) were orally administered in hyperprolactinemic patients. Mean serum prolactin concentration was significantly decreased between 120 and 240 min following the ingestion of all three drugs in comparison with a placebo; a consistent reduction to below 50% of basal values occurred in 10 of 14 patients after metergoline, in 5 of 10 after methysergide, and in 11 of 14 after bromocriptine administration. These data indicate that serotonin antagonists may acutely lower serum prolactin levels in hyperprolactinemic patients similarly to bromocriptine, though their mechanism of action is most likely different.

Citing Articles

Validity of urinary monoamine assay sales under the "spot baseline urinary neurotransmitter testing marketing model".

Hinz M, Stein A, Uncini T Int J Nephrol Renovasc Dis. 2011; 4:101-13.

PMID: 21912487 PMC: 3165907. DOI: 10.2147/IJNRD.S22783.


Effect of metergoline on serum prolactin stimulated by TRH.

Iannotta F, Gadaleta G, Pollini C, Vettaro M J Endocrinol Invest. 1980; 3(3):301-3.

PMID: 6776182 DOI: 10.1007/BF03348280.


Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine.

Quattrone A, Tedeschi G, Aguglia U, Scopacasa F, Direnzo G, Annunziato L Br J Clin Pharmacol. 1983; 16(5):471-5.

PMID: 6639832 PMC: 1428066. DOI: 10.1111/j.1365-2125.1983.tb02202.x.


Effect of dihydroergokryptine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic and acromegalic subjects: evidence of potent and long-lasting pituitary dopamine receptor stimulation.

Ferrari C, Rampini P, PARACCHI A, Boghen M, Mailland F Eur J Clin Pharmacol. 1985; 27(6):707-11.

PMID: 3921384 DOI: 10.1007/BF00547054.


Drug-induced changes in prolactin secretion. Clinical implications.

Hell K, Wernze H Med Toxicol Adverse Drug Exp. 1988; 3(6):463-98.

PMID: 3063922 DOI: 10.1007/BF03259897.